With roughly 30 cases over AndroGel now pending in the Northern District of Illinois, plaintiffs have requested that all similar testosterone lawsuit filings be transferred there for pretrial proceedings, court documents indicate.

In a brief filed on March 28th, 2014, plaintiffs in these cases assert that a federal multidistrict litigation (MDL) in the U.S. District Court, Northern District of Illinois is necessary for claims filed over the hormone-raising therapy, given that the number of AndroGel-related suits may be on the rise. They go on say that centralizing these claims, which similarly allege the risk for strokes, heart attacks, blood clots and other injuries caused by the testosterone treatment therapy, will help to conserve the resources of the court in handling thousands of lawsuits that may be filed in the future. According to AndroGel lawsuit plaintiffs, additional cases have also been filed in federal jurisdictions in Pennsylvania and Colorado.

Court records indicate that the recent brief, which was submitted to the U.S. Judicial Panel on Multidistrict Litigation (JPML), follows an Order on March 14th from the Executive Committee of the U.S. District Court, Northern District of Illinois that all claims filed in the jurisdiction be consolidated before a single judge.

AndroGel Lawsuits Allege Strokes, Heart Attacks and other Injuries

It is noteworthy to add that all AndroGel lawsuits currently pending in Illinois federal court were filed after the U.S. Food and Drug Administration (FDA) announced in January 2014 that it was reviewing certain “Low T” testosterone therapy treatments.  Plaintiffs in cases over AndroGel allege that it was aggressively marketed by its manufacturer as a treatment for low libido, fatigue, and other symptoms associated with aging, causing it to be prescribed to men without a serious medical need. Their suits point out that “Low T” treatments like AndroGel are only approved by the FDA to treat low testosterone levels in conjunction with a serious medical condition, such as hypogonadism.

In addition to cases over AndroGel, the medication, Testim is also now involved in several testosterone lawsuits. Court records indicate that two claims were filed in March 2014 in the U.S. District Court, Eastern District of Pennsylvania, and another was filed on February 26th in California federal court.

Filing a Testosterone Lawsuit

If you were prescribed AndroGel, Testim or another “Low T” treatment therapy, you may be eligible to file a claim against its manufacturer. Call our Firm today at (877) 779-1414 to learn more.

Published April 9, 2014 by